RxDoctor Payments Data

Mandy Selders

Nurse Practitioner · Chambersburg, PANPI 1992347454

Payments from drug & device makers

$3,664in general payments, 2019–2025

Across 181 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$968
  • Otsuka America Pharmaceutical, Inc.$717
  • Axsome Therapeutics, Inc.$574
  • Alkermes, Inc.$346
  • Takeda Pharmaceuticals U.S.A., Inc.$230
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
  • plus $604 from 6 others

What the payments were for

  • Food & beverage$3,61799%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,664 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$9,537
Medicare patients
22
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole11$15,802
TrintellixVortioxetine Hydrobromide17$7,991
Duloxetine Hcl82$4,255
Aripiprazole60$2,027
Bupropion XlBupropion Hcl104$1,498
Hydroxyzine Hcl68$1,211
Vilazodone Hcl11$1,150
Trazodone Hcl83$718
Buspirone Hcl59$692
Prazosin Hcl25$619
Bupropion Hcl SrBupropion Hcl26$617
Venlafaxine Hcl ErVenlafaxine Hcl43$602
Divalproex Sodium ErDivalproex Sodium24$461
Fluoxetine Hcl16$393
Sertraline Hcl45$300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$717$15,80211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$230$7,99117 claims
Almatica Pharma LLCSertraline Hcl$82$30045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Chambersburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →